As compared to the classical approaches with drugs that target the extra- or intracellular domains of NRP receptors [49,50] or their ligand-binding site, inhibition of NRP1-mediated signaling platforms by disrupting the interaction of NRP1 with itself and with other receptors within the membrane represents a novel concept that has been proven to inhibit tumor angiogenesis [47]. Here, NRP1 is linked to neoplasm.